Stay updated on Safety and Efficacy of Sparsentan in IgA Nephropathy Clinical Trial
Sign up to get notified when there's something new on the Safety and Efficacy of Sparsentan in IgA Nephropathy Clinical Trial page.

Latest updates to the Safety and Efficacy of Sparsentan in IgA Nephropathy Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedMinor changes include the addition of Revision: v3.4.2 and the removal of a funding notice, which do not affect the study data, status, or history. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.9%

- Check21 days agoChange DetectedAdded a site-wide notice about government funding status and updated the revision history to v3.4.1, removing the previous v3.4.0 entry.SummaryDifference0.9%

- Check28 days agoChange DetectedThe history page now includes a glossary toggle, color-coded highlights for additions (green) and deletions (red), and an updated revision label showing v3.4.0.SummaryDifference1%

- Check42 days agoChange DetectedRecord History now shows revision v3.3.4 and removes revision v3.3.3.SummaryDifference0.1%

- Check63 days agoChange DetectedThe page footer now displays Revision: v3.3.3, and the HHS Vulnerability Disclosure link and Revision: v3.3.2 have been removed.SummaryDifference0.2%

- Check92 days agoChange DetectedA new revision entry v3.3.2 was added and an older revision v3.2.0 was removed from the Record History.SummaryDifference0.1%

Stay in the know with updates to Safety and Efficacy of Sparsentan in IgA Nephropathy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety and Efficacy of Sparsentan in IgA Nephropathy Clinical Trial page.